The relative survival benefits and postoperative mortality among the different types of neoadjuvant treatments (such as chemotherapy only, radiotherapy only or chemoradiotherapy) for esophageal cancer patients are not well established. To evaluate the relative efficacy and safety of neoadjuvant therapies in resectable esophageal cancer, a Bayesian network meta-analysis was performed. MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials were searched for publications up to May 2016. ASCO and ASTRO annual meeting abstracts were also searched up to the 2015 conferences. Randomized controlled trials that compared at least two of the following treatments for resectable esophageal cancer were included: surgery alone, surgery preceded by neoadjuvant chemotherapy, neoadjuvant radiotherapy or neoadjuvant chemoradiotherapy. The primary outcome assessed from the trials was overall survival. Thirty-one randomized controlled trials involving 5496 patients were included in the quantitative analysis. The network meta-analysis showed that neoadjuvant chemoradiotherapy improved overall survival when compared to all other treatments including surgery alone (HR 0.75, 95% CR 0.67-0.85), neoadjuvant chemotherapy (HR 0.83. 95% CR 0.70-0.96) and neoadjuvant radiotherapy (HR 0.82, 95% CR 0.67-0.99). However, the risk of postoperative mortality increased when comparing neoadjuvant chemoradiotherapy to either surgery alone (RR 1.46, 95% CR 1.00-2.14) or to neoadjuvant chemotherapy (RR 1.58, 95% CR 1.00-2.49). In conclusion, neoadjuvant chemoradiotherapy improves overall survival but may also increase the risk of postoperative mortality in patients locally advanced resectable esophageal carcinoma.
Esophageal carcinoma mainly comprises squamous cell carcinoma (SCC) in the upper one-third or middle of the esophagus, or as adenocarcinoma (AC) in the lower one-third or where the esophagus meets the stomach. Surgical resection is believed to be an important component for curative management, but surgical resection alone results in an unfavorable 5-year survival rate of 25%.
1 Therefore, the management and treatment of esophageal carcinoma has been evolving to include additional therapies such as neoadjuvant chemotherapy (CT), radiation therapy (RT) and combined chemotherapy and radiation therapy (CRT).
Advances in neoadjuvant treatment and the results of recent publications have directed oncologists toward a more frequent and conventional use of neoadjuvant treatment. For instance, several randomized control trials (RCTs) have demonstrated the survival benefit of each treatment compared with surgery alone. [2] [3] [4] [5] [6] Gebski et al. demonstrated that neoadjuvant CRT, when compared to surgery alone, was associated with a significant 19% relative risk reduction in all-cause mortality, corresponding to 13% absolute improvement in survival at 2 years; while neoadjuvant CT, when compared to surgery alone, was associated with a borderline significant 10% relative risk reduction in all-cause mortality and 7% improvement in survival at 2 years. 7 A recent meta-analysis by Sjoquist et al. also suggests a survival benefit for neoadjuvant CRT or CT over surgery alone. 8 At present, there is paucity of evidence directly comparing neoadjuvant CRT with neoadjuvant CT. The optimal choice between neoadjuvant CRT and CT remains unclear with scant high-quality evidence to help direct clinicians. The three small sample sized RCTs that did directly compare these modalities did not produce statistically significant results. [9] [10] [11] A recent meta-analysis by Sjoquist et al. was also unable to confirm the superiority of neoadjuvant CRT compared to neoadjuvant CT, recommending that further research was needed to examine this issue. 8 When there is a paucity of RCTs directly comparing treatment modalities, network meta-analyses (NMA) can be used to synthesize all the available evidence. Unlike conventional meta-analyses, NMAs can simultaneously compare multiple treatment modalities and incorporate both direct and indirect evidence into the analysis. NMAs are gaining popularity and have been recently conducted in a number of oncology settings including metastatic breast cancer, 12 metastatic colon cancer 13 and metastatic pancreatic cancer.
14 In esophageal cancer, there is a paucity of RCTs comparing neoadjuvant CRT to neoadjuvant RT directly, or comparisons of neoadjuvant CT to neoadjuvant RT. However, these treatments have all been compared against surgery alone, which can be used as the common comparator to allow for indirect comparisons among each other. NMAs can overcome sample size limitations and often times heterogeneous patient populations to generate direct and indirect comparisons. 15 Additionally, NMAs extend the study population over a broad range, thus increasing the studies' generalizability. Therefore, we performed an NMA of RCTs to evaluate the relative efficacy and safety of neoadjuvant therapies in resectable esophageal cancer.
Materials and Methods

Search strategy
The MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL) databases and ASCO and ASTRO abstracts were searched for RCTs up to May 2016. RCTs that compared at least two of the following treatments for resectable esophageal cancer were included: surgery alone, surgery preceded by neoadjuvant CT, neoadjuvant RT or neoadjuvant CRT. Articles of any language were considered. All types of surgery, CT and RT were included. However, only treatments that administered CT and/or RT prior to surgery, and for which the treatments received were the primary care, were considered. All eligible patients had esophageal cancer with squamous cell carcinoma, adenocarcinoma or undifferentiated carcinoma. 16 Exclusion criteria included the following: nonresectable or metastatic esophageal cancer, any postoperative treatment, any prior intervention other than diagnostic biopsy and nonrandomized trials. The literature search strategy used is outlined in Supporting Information (eMethods).
Data extraction
Two reviewers independently scanned full reports which met the inclusion criteria previously delineated. Discrepancies in study inclusion were resolved through discussion with a third reviewer. Outcomes assessed from the RCTs included overall survival (OS), postoperative deaths (i.e., 30-day mortality) and any patterns of recurrence (i.e., locoregional recurrence and/or distant metastases and/or locoregional recurrence plus distant metastases). Locoregional recurrence was defined as relapse at the primary site, including the anastomosis or in regional lymph nodes. Distant metastases were defined as distant lymph node sites or involvement of distant organs including lung, liver, bone and subcutaneous tissue. The primary outcome was OS expressed as a hazard ratio (HR). If HRs were not reported in the publications (i) the log hazard ratio and standard error (SE) from the available summary statistics were calculated using methods outlined by Parmar et al., 17 (ii) data were requested from the study authors or (iii) data were extracted from the Kaplan-Meier curves using DigitizeIt software, according to the methods outlined by Parmar et al. 18 HRs were extracted for survival data (i.e., OS), while risk ratios (RR) were calculated for patterns of recurrence and postoperative mortality. For the included studies, assessment of risk of bias was conducted by two independent reviewers using the Cochrane risk of bias assessment tool. 19 Any discrepancies were resolved through consensus with a third reviewer. Sensitivity analyses for OS were also performed to test the robustness of our results. In our first sensitivity analysis, only published trials were included to ensure accuracy as interim data presented in meeting abstracts can often differ from the final results. 20 In our second sensitivity analysis, trials that evaluated noncontemporary types/doses of chemotherapy and radiotherapy based on current standards were excluded. For instance, the use of older agents such as mitomycin C, bleomycin and vinblastine have been shown to be ineffective in combination with cisplatin. 6, 21 Furthermore, the use of a 20
Gy radiation dose is the current palliative standard and would be insufficient in a potentially curative regimen. Therefore, these treatments were excluded to derive results
What's new?
The relative survival benefits and postoperative mortality among the different types of neoadjuvant treatments (such as chemotherapy alone, radiotherapy alone or chemoradiotherapy) for esophageal cancer patients are still not well established. To evaluate the relative efficacy and safety of neoadjuvant therapies in resectable esophageal cancer, here the authors performed a Bayesian network meta-analysis of 31 randomized controlled trials. Neoadjuvant chemoradiotherapy followed by surgery showed a statistically significant survival advantage over neoadjuvant radiotherapy, neoadjuvant chemotherapy and surgery alone. The results of this analysis support a more pronounced use of multimodal neoadjuvant therapies for the treatment of locally advanced, resectable esophageal cancer.
that might be more relevant to current practice. In the final sensitivity analysis, two pivotal trials (MAGIC and FNCLCC/ FFCD) that evaluate perioperative were included. 22, 23 Given that only 42% of patients in the MAGIC trial and 50% of patients in the FNCLCC/FFCD trial received the postoperative part of the therapy, it is arguable that a large portion of the benefits observed are derived from the neoadjuvant parts of the treatments.
Statistical analysis
Pairwise comparisons of the neoadjuvant regimens from the trials were conducted based on direct evidence using RevMan software (version 5.3.5). A network comparison was then performed using a Bayesian model that combines likelihoods to synthesize results from direct and indirect evidence of multiple interventions simultaneously. In the absence of direct comparison trials, a posterior probability distribution of the parameters was produced from pooling likelihoods as a function of the parameters with a prior probability distribution, which provided a network estimate to calculate the most effective treatment. The noninformative prior distributions used in this analysis include: uniform (0,2) for standard deviation of the random effects model and normal (0, tau 5 0.0001) for log [HR] . An effect size was also calculated, which provided an increased precision than that of any one type of evidence alone.
The Bayesian network meta-analysis was performed using the Bayesian Markov Chain Monte-Carlo (MCMC) sampling in version 1.4.3 of WinBUGS. 24 In WinBUGS, 3 chains were fit with 40,000 burn-ins and 40,000 iterations each. Subgroup analysis for histology was also conducted by modeling histology (adenocarcinoma vs squamous cell carcinoma) as a covariate to the Bayesian meta-regression. The results of these analyses were reported in accordance to the guidelines outlined by the Quality of Reporting of Meta-analyses (QUOROM) and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). 25, 26 The significance of any discrepancies in the estimates of the treatment effects from the different trials was assessed by means of Cochran's test for heterogeneity and the I 2 statistic.
Results
Trial characteristics
A PRISMA diagram summarizes the literature search results and the selection process for the studies included in the NMA (Supporting Information, eFig. 1). In total, 31 randomized controlled trials were obtained for the final quantitative metaanalysis (N 5 5496 patients).
2-6,9-11,21,27-48 All trials included were randomized and followed intention-to-treat analysis for the primary endpoints. The study characteristics of the publications included in the meta-analysis are shown in Supporting Information, eTable 1. The treatment strategy network is shown in Figure 1 . Briefly, 30 studies were fully published reports and 1 trial was only published in the abstract form. 33 Two publications were a 2 3 2 factorial comparison of neoadjuvant CT, neoadjuvant RT, neoadjuvant CRT and surgery alone. 32, 42 Adverse effects of the four-neoadjuvant treatments were not consistently reported. In general, the most common adverse effect of treatment was postoperative mortality (i.e., 30-day mortality), for which the risk ratio was included in our analysis.
Risk of bias assessment
Two independent reviewers evaluated the quality of evidence reported in each study using the Cochrane risk of bias tool (Supporting Information, eFig. 3). As all the studies included in the NMA were randomized, selection and attrition bias were minimized. Moreover, there was no significant imbalance in loss to follow-up between the intervention and control groups of the included trials, further reducing attrition bias. As expected, blinding of outcome assessors was not explicitly indicated. The majority of studies had OS as the primary endpoint, reducing detection bias as the outcome assessor would not influence this endpoint. However, there is potential for some selection bias, as allocation concealment was not explicitly mentioned in majority of the studies.
Direct pairwise comparison analysis
In total, 9 studies directly compared neoadjuvant CT to surgery alone ( Supporting Information, eTable 1) . The direct comparison including these trials showed a strong trend but not a statistically significant OS benefit of neoadjuvant CT (HR 0.90, 95% 0.81-1.01). In contrast, neoadjuvant CRT demonstrated a superior OS over surgery alone (HR 0.75, 95% CI 0.65-0.85). However, 3 trials that directly compared neoadjuvant CRT to Figure 1 . Network of direct pairwise comparisons. The node size corresponds to degree centrality (more trials involving a particular intervention increases the node size). The numbers within the nodes represent the number of randomized patients for that modality. S, surgery alone; CT 1 S, neoadjuvant chemotherapy followed by surgery; CRT 1 S, neoadjuvant chemoradiotherapy followed by surgery; RT 1 S, neoadjuvant radiotherapy followed by surgery. [Color figure can be viewed at wileyonlinelibrary.com] neoadjuvant CT did not show a statistically significant OS difference (HR 0.88, 95% CI 0.63-1.22). Similarly, neoadjuvant RT without any chemotherapy also did not show an OS benefit (HR 0.93, 95% CI 0.80-1.08).
Compared to surgery alone, none of the neoadjuvant interventions led to a statistically significant increase in postoperative mortality in the direct pairwise comparisons, even though there are trends of increase risks with wide confidence intervals (Table 1) . Furthermore, the direct comparison between neoadjuvant CRT and neoadjuvant CT also showed no significant difference in postoperative mortality or patterns of recurrence (local and distant). A statistically significant improvement in locoregional recurrence was only observed for neoadjuvant CRT when compared to surgery alone (RR 0.57, 95% CI 0.43-0.75). Forest plots of overall survival for the included studies are presented in Supporting Information, eFig 4. Forest plots for all other pairwise comparisons are presented in Supporting Information, eFigs. 5-8.
Network meta-analysis
The Bayesian analysis shows a strong and favorable OS benefit toward neoadjuvant CRT compared to both resection alone and the other neoadjuvant interventions (Figure 2a) . Notably, our NMA has established a significant survival advantage of neoadjuvant CRT over neoadjuvant CT (HR 0.83, 95% CR 0.70-0.96), which had not been previously demonstrated in the direct pairwise analysis (Table  1 ). In fact, the Bayesian analysis found a 97.5% probability of neoadjuvant CRT being the best treatment with regards to OS (Supporting Information, eFig. 9). Neoadjuvant CT and RT were comparable as second-best regimens according to the calculated probabilities, with no significant difference between the two (HR 0.99, 95% CR 0.83-1.22). Last, the NMA was also consistent with the pairwise analysis in showing a trend but not a statistically significant OS benefit of neoadjuvant CT compared to surgery alone (HR 0.91, 95% CR 0.81-1.04).
Although OS was improved for neoadjuvant CRT compared to other interventions, the NMA did reveal an increased risk for postoperative mortality when comparing neoadjuvant CRT to either surgery alone (RR 1.46, 95% CR 1.00-2.14) or to neoadjuvant CT (RR 1.58, 95% CR 1.00-2.49). The NMA also showed improvement in locoregional recurrence when comparing neoadjuvant CRT to surgery 
Sensitivity and subgroup analysis
A sensitivity analysis including only the 30 published trials shows similar results to the full NMA with neoadjuvant CRT providing a significant OS benefit over neoadjuvant CT and surgery alone (Supporting Information, eFig. 2). However, unlike the full NMA, a statistically significant result was not observed when comparing neoadjuvant CRT to neoadjuvant RT (HR 0.83, 95% CR 0.68-1.02). A second sensitivity analysis was conducted excluding trials that administered treatments not commonly prescribed such as mitomycin C or vineblastine or bleomycin in combination with cisplatin and/or used 20 Gy for neoadjuvant RT or CRT ( Supporting Information, eFig. 2) . In contrast to the full NMA, the results of this analysis showed a statistically significant benefit for neoadjuvant CT over surgery alone (HR 0.85, 95% CR 0.72-0.98). However, a significant benefit of neoadjuvant CRT over neoadjuvant CT was not observed (HR 0.87, 95% CR 0.71-1.06). The widening of the confidence interval leading to an insignificant result can be attributed to fewer trials (n 5 21) being included in the network for this sensitivity analysis compared to the primary analysis (n 5 31).
In the final sensitivity analysis, two pivotal trials that compare perioperative chemotherapy to surgery alone-the UK Medical Research Council MAGIC trial and the French FNCLCC/FFCD trial-were included in the NMA. The addition of these two trials in this sensitivity analysis did not significantly alter our results, with neoadjuvant CRT maintaining its superiority over the other interventions (Supporting Information, eFig. 2).
A subgroup analysis regarding patient pathology was also performed (Supporting Information, eTable 2). Consistent with the NMA data, the Bayesian analysis provides evidence for better OS for neoadjuvant CRT than surgery alone regardless of pathology type. When comparing neoadjuvant CRT to neoadjuvant CT, patients with squamous cell carcinoma derived a statistically significant OS benefit (HR 0.83, 95% CR 0.70-0.97).
Discussion
Based on the analysis of both the direct pairwise comparisons and the NMA, neoadjuvant CRT had the highest probability of being the best regimen in terms of OS. While several meta-analyses have established the survival benefit of neoadjuvant CRT over surgery alone, the results of our NMA has uniquely confirmed that neoadjuvant CRT provides superior OS compared to neoadjuvant CT. Although evidence supporting the use of neoadjuvant CRT over CT has been examined in 3 randomized phase II trials, they were unable to show a statistically significant survival advantage for the neoadjuvant intervention. [9] [10] [11] Furthermore, the direct evidence using direct pairwise meta-analysis, consisting of only these 3 trials, was also unable to show any statistically significant benefits (Table 1) . Conducting an NMA allowed an increase in power and improved precision by incorporating information from all the trials included in the network, rather than relying on the 3 RCTs alone. The network results were bolstered by data from indirect comparisons that incorporated results from all trials with a sample size of 5,496 patients, compared to only 3 head-to-head trials with 375 patients.
While this NMA showed improvement in long-term survival for patients treated with neoadjuvant CRT compared to the other interventions, neoadjuvant CRT was also associated with increased risk of postoperative mortality when compared to neoadjuvant CT or surgery alone. Conflicting evidence currently exists regarding the effect of neoadjuvant CRT on postoperative mortality with some studies reporting an increased risk 49 and others describing no significant change. 8 Therefore, future studies that directly evaluate postoperative outcomes, particularly in patients receiving neoadjuvant CRT, are warranted.
The survival advantage of multimodal therapy has been suggested in several meta-analyses. 7, 8, 49 However, these metaanalyses focused only on direct comparisons of neoadjuvant CRT against surgery alone. For example, while the results of the meta-analysis by Sjoquist et al. suggested survival benefit for neoadjuvant CRT or CT over surgery alone, they were not able to demonstrate a statistically significant survival benefit of neoadjuvant CRT against neoadjuvant CT.
8 Compared to Sjoquist et al., our primary analysis (direct and indirect) did not find a statistically significant benefit of neoadjuvant CT over surgery alone. This difference can be attributed to Sjoquist et al. including the FNCLCC/FFCD trial in their primary analysis, while we excluded this trial for evaluating a perioperative and not a strictly postoperative chemotherapy regimen. When this trial along with the MAGIC trial were included as part of our sensitivity analysis, a significant result for neoadjuvant CT versus surgery alone was observed (HR 0.87, 95% CI 0.78-0.98). Similar to our primary analysis, Sjoquist et al. did conclude a positive survival advantage for multimodal therapy involving neoadjuvant CRT compared to surgery alone.
Currently, there are only two active trials comparing neoadjuvant CRT to neoadjuvant CT for esophageal cancer, 50, 51 with one being a pilot study. 50 Owing to sample size limitations, it will be challenging to conduct a large-scale trial to directly compare these interventions. Therefore, this network meta-analysis likely provides the best available evidence for the use of neoadjuvant CRT.
There are a few limitations of this analysis that need to be addressed. First, our conclusions are based on published group data rather than individual patient information, which may allow for more analyses to adjust for differences in patient characteristics. While OS was reported in all trials, other metrics were not consistently reported. Thus, there were limited precisions of our estimates for postoperative mortality and recurrence rates as our results are based on a limited sample size. Additionally, although the eligibility criteria specified the inclusion of RCTs only, randomization methods were not consistently reported, limiting our ability to sufficiently categorize risk of bias from all trials. Last, in the subgroup analysis performed based on pathology, AC and SCC were analyzed together and not as separate diseases with adjustments based on the proportion of patients having either pathology in each trial. While AC and SCC may exhibit different epidemiological features and biological behaviors, applying the Bayesian analysis separately to these pathologies is challenging due to the lack of complete reporting of the subgroups in literature. As a result of this limited data, there is potential for reporting bias and the lack of power to conduct separate subgroup analyses. Our approach of adjusting for the proportion of AC vs SCC in each trial in a Bayesian framework allows us to borrow strength from all data and improve precision. To demonstrate robustness of our results, a subgroup analysis separating the pathologies is shown in the supplement (Supporting Information, eTable 3).
As expected, the findings are consistent without our initial results but confidence intervals have widened, showing a reduction in precision.
In conclusion, our synthesis of the 31 trials demonstrates that neoadjuvant CRT provides a survival advantage for patients with locally advanced, resectable esophageal cancer. For clinical practice, our results provide statistical evidence based on the totality of the literature to support the use of neoadjuvant chemoradiotherapy as the standard of care for the treatment of locally advanced, resectable esophageal cancer for patients who are fit for such treatment, and where clinicians and patients are willing to accept a slight increased risk of postoperative mortality.
